Allergic Diseases: Pipeline Offers Novel Approaches to Treat Increasingly Prevalent Conditions, with Strong Presence of Cytokine Mediators Among First-in-Class Products

2019-06-10
Price :
Published : Jun-2019
No. of Pages : 79

Allergic Diseases: Pipeline Offers Novel Approaches to Treat Increasingly Prevalent Conditions, with Strong Presence of Cytokine Mediators Among First-in-Class Products

Summary

An allergy or allergic disease is a condition that arises from an adverse reaction to an exogenous antigen, a substance that invokes an immunological response. These conditions are extremely common. The number of people diagnosed with allergic diseases is rising rapidly on a global scale, which is attributable to factors such as population growth and increased urbanization and pollution. In addition, for a minority of these patients, allergic reactions can be severe, debilitating, or even life-threatening.

Despite this high disease burden, treatment options are limited for many conditions and patients often receive insufficient treatment or no treatment at all. This accentuates the need to identify novel molecular targets and mechanisms of action that could lead to more effective treatments. This report assesses innovation within the pipeline for a wide range of allergic diseases, with a particular focus on five key indications – allergic rhinitis, allergic asthma, allergic conjunctivitis, atopic dermatitis and food allergies.

Scope

– There are 414 programs in active development across all allergic diseases. What proportion of these products are first-in-class? How many programs are in development for each of the five key indications?
– Cytokine signaling is the most prominent molecular target class in the first-in-class pipeline. Which other target classes are featured in the first-in-class pipeline? How does the distribution of target classes differ in terms of development stage?
– Of the five key indications, the atopic dermatitis pipeline has the most first-in-class targets, followed by allergic asthma. Which key indication has the least first-in-class targets? Are there any first-in-class targets represented in the pipeline for more than one key indication?
– Across the allergic diseases landscape, there are 297 active companies. Which companies have formed partnerships? Which companies have first-in-class assets in development with no prior deal involvement?

Reasons to buy

– Understand the current disease landscape with an in-depth discussion of etiology, pathophysiology, disease classification, and epidemiology for each of the key indications. An overview of market therapies for allergic diseases is also provided.
– Analyze the pipelines for allergic diseases overall, as well as each of the five key indications, and stratify them by stage of development, molecule type, and molecular target.
– Assess the therapeutic potential of first-in-class molecular targets. Using proprietary matrix assessments, first-in-class molecular targets for each of the five key indications have been assessed and ranked according to clinical potential. Promising first-in-class targets have been reviewed in greater detail.
– Analyze company strategies in prior deals through case studies of key deals for first-in-class products for allergic diseases, and recognize commercial opportunities by identifying first-in-class pipeline products that have not yet been involved in licensing or co-development deals.

Filed in: Pharmaceutical
Publisher : GlobalData
More Reports
Title Price Buy Now

Ambulatory Surgical Centers Market by Product (EHR, Practice Management, Telehealth, Healthcare Analytics, PHM, Supply Chain Management, RCM, Surgical planning, Quality Management), Specialty Type (Single, Multi-specialty) – Global Forecast to 2025

The Ambulatory Surgical Centers market is projected to reach USD 7.2 billion by 2025 from 2.1 billion in 2020 at a CAGR of 27.6% during the forecast period.There is a growing inclination across the globe towards the adoption of healthcare IT technologies due to the increasing need to deliver quality care to patients while curtailing escalating healthcare costs. These robust IT solutions are designed to streamline workflow in healthcare systems, reduce expenses, and facilitate compliance with stringent regulatory guidelines. By-products and services, the healthcare providers segment accounted for the largest share of the Ambulatory Surgical Centers market in 2018 Based on products and services, the Ambulatory Surgical Centers market is segmented into healthcare provider solutions, h......
$5650

Risk-based Monitoring Software Market by End User (Pharma & Biopharmaceutical Co., Medical Device Co., CROs), Delivery Mode (Web Hosted, On-premise, Cloud-based), Type (Enterprise, Site), Component (Software, Services) – Global Forecast to 2025

“Risk-based monitoring (RBM) software market is projected to grow at a CAGR of 13.3%.” The RBM software market is expected to reach USD 511 million by 2025 from USD 273 million in 2020, at a CAGR of 13.3% during the forecast period. The RBM software market has witnessed various advancements in products and their approvals to meet the needs of the pharmaceutical research and development industry worldwide. Growth in the market can primarily be attributed to factors such as the cost and time efficiency of RBM solutions, rising number of clinical trials, and increasing government funding and grants to support clinical trials “The Enterprise RBM Software segment to hold the largest market share in 2020.” Based on type, the RBM software market is segmented into Enterprise RB......
$5650

Veterinary Vaccines Market by Disease (Swine Pneumonia, Avian Influenza, Rabies, Coccidiosis, Brucellosis, Canine Distemper), Type (Poultry, Livestock, Aquaculture, Porcine, Canine), Technology (Inactivated, Toxoid, Recombinant) – Global Forecast to 2025

“The veterinary vaccines market is projected to grow at a CAGR of 7.2% during the forecast period (2020–2025).” The global veterinary vaccines market size is projected to reach USD 11.3 billion by 2025 from USD 8.0 billion in 2020, at a CAGR of 7.2%. The growth of this market is driven majorly by factors such as the initiatives by various government agencies and animal associations to maintain animal health, rising incidence of zoonotic diseases, growth in the companion animal population, and the rising demand for animal-derived food products are driving the growth of this market. On the other hand, the high storage cost of vaccines is restraining market growth. “By technology, the recombinant vaccines segment is expected to grow at the highest CAGR during the forecast period......
$4950

COVID-19 Impact on Vaccines & Drugs Market – Global Forecast to 2025

"The global COVID 19 vaccines market is projected to grow at a CAGR of -14.9% during the forecast period." The global COVID-19 vaccines market is projected to reach USD 1,401 million by 2025 from USD 2,273 million in 2022, at a CAGR of -14.9% during the forecast period. The growth of the global COVID-19 vaccines market is majorly attributed to the increasing number of people infected with COVID-19 and growing funding for vaccine development. "The global COVID 19 drugs market is projected to grow at a CAGR of -57.8% during the forecast period." The global COVID-19 drugs market is projected to reach USD 2 million by 2025 from USD 165 million in 2020, at a CAGR of -57.8% during the forecast period. The growth of COVID-19 drugs market is attributed primarily to use of repurposed drugs......
$5650

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2020 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2020 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for March 2020 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in March 2020. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides ......
$1000

Colorectal Cancer: Global Drug Forecast and Market Analysis to 2028

Colorectal Cancer: Global Drug Forecast and Market Analysis to 2028 Summary Colorectal cancer (CRC) occurs in the large intestine or large bowel. It is the third most common cancer globally and is one of the most common causes of cancer deaths in the world. Early stage CRC is commonly treated with surgery, while metastatic colorectal cancer (mCRC) treatment is dominated by fluorouracil chemotherapy regimens in combination with angiogenesis inhibitors, primarily Roche's Avastin, and epidermal growth factor receptor (EGFR) inhibitors. GlobalData valued the CRC market at $6.4B in 2018. This market is defined as sales of generic chemotherapy and major branded drugs commonly prescribed for CRC patients across the 8MM. GlobalData expects the market to increase to $8.1B in 2028 at a Compound A......
$10995

Coronavirus Disease 2019 (COVID-19) Sector Forecast: Analyst Consensus Sales Forecast

Coronavirus Disease 2019 (COVID-19) Sector Forecast: Analyst Consensus Sales Forecast Summary This report contains a summary of the analyst consensus forecasts available in the GlobalData Pharma Intelligence Center Drug Sales and Analyst Consensus Database for the Indication COVID-19. Despite the rapid development of COVID-19 therapies being developed the majority of the COVID-19 pipeline is in early stage development so there are few forecasts available. Currently there are three drugs indicated for COVID-19 which have analyst consensus forecasts available. Scope This 27-page report gives important, expert insight you won't find in any other source. 7 figures throughout the report illustrate major points and trends in COVID sales forecasts and company pipelines. This report is require......
$495

Medical Marijuana: Consumers’ Perspectives in the US and UK

Medical Marijuana: Consumers' Perspectives in the US and UK Summary GlobalData's Medical Marijuana, Consumers' Perspectives report combines an extensive survey and analysis of patients' perspectives in the US and UK to provide an in-depth consumer-centered review of the medical marijuana market. Components of the report include an in-depth breakdown of the survey and its respondents, detailed analysis of consumers' concerns and opinions of medical and recreational marijuana, information from interviews with patients receiving treatment with medical marijuana in the US and UK, and an assessment of the impact of the COVID-19 pandemic on the medical marijuana space. The report evaluates trends across different age groups, health statuses, and other parameters to inform insightful compariso......
$7995

Pharmaceutical Trade and Supply Chain Survey – Q1 2020: Coronavirus Disease 2019 (COVID-19) Sector Impact

Pharmaceutical Trade and Supply Chain Survey - Q1 2020: Coronavirus Disease 2019 (COVID-19) Sector Impact Summary GlobalData's Coronavirus Disease 2019 (COVID-19) Sector Impact: Pharmaceutical Trade and Supply Chain Survey - Q1 2020 provides in-house analyst expertise on the results of a 5 minute survey of 136 GlobalData Pharma clients and prospects, which was fielded from March 13, 2020 to March 24, 2020. Scope - This report provides an assessment of how the pharmaceutical industry perceives the supply chain disruption caused by the COVID-19 pandemic, including the challenges associated with clinical trials, logistics, API and finished dose manufacturing. - Since the first case was diagnosed in Wuhan, China, in December 2019, COVID-19 cases have continued to rise rapidly across the gl......
$1495

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Russia

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Russia Summary GlobalData, the industry analysis specialist, has released its latest report: "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Russia". The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in Russia. It identifies the key trends in the country's healthcare market and provides insights into its demographic, regulatory, and reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis by Glo......
$1995
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy